<DOC>
	<DOC>NCT00154700</DOC>
	<brief_summary>The primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma patients who need palliative Chemotherapy.</brief_summary>
	<brief_title>Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer</brief_title>
	<detailed_description>The primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma patients who need palliative Chemotherapy. The secondary objectives include overall survival, progression-free survival, and toxicity.</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Pathologically proven esophageal squamous cell or adenocarcinoma Recurrence or metastasis Measurable disease (&gt; 1 X 1 cm) by CXR, CT scan or MRI,Age &gt; 18, KPS &gt; 60% , Cre &lt; 1.5mg/dl, AST/ALT &lt; 3.5 X N, Bil &lt; 2.0mg/dl WBC &gt; 4,000/mm3, ANC &gt; 2,000/ mm3, Plt &gt; 100,000/mm3 Prior chemo (except as radiosensitizers)Recurrent, treated esophageal lesion only (except &gt; 2 months)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Combination,Chemotherapy,Esophageal Cancer</keyword>
</DOC>